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Abstract
Introduction: HIV pre-exposure prophylaxis (PrEP) is not available on the National Health Service (NHS) in England.
People are buying generic versions of tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) on the internet, which is
legal under UK import laws.
Methods: HIV-negative individuals attending our clinic who reported purchasing generic PrEP online were provided with
risk-reduction advice and were evaluated for HIV, hepatitis B and C, renal function and sexually transmitted infections
(STIs)on their first visit. They were offered regular follow-up visits every 3 months and given risk-reduction advice. Plasma
therapeutic drug monitoring (TDM) for tenofovir and FTC was also offered.
Results: 641 individuals accessed the service during 2016–2017. Median time on generic PrEP was 202 days. All were
MSM, 81% were white, 75% used PrEP daily and 14% on an event-driven basis, and 67% were on generic TDF/FTC
manufactured by Cipla Ltd. There were no serious adverse events. Thirty-nine percent of individuals (191/494) reported
using recreational drugs in the 12 months before starting PrEP, and 29% (127/443) reported this while taking PrEP.
During follow-up, 26% (142/552) of individuals were diagnosed with an STI at one or more follow-up visits. In 336
person-years of follow-up, there were no cases of HIV infection (0%, 95% CI 0%–1.1%). There were no new cases of
hepatitis B and two new cases of hepatitis C.
Discussion: There were no new cases of HIV in 641 individuals using generic PrEP. At the same centre, new HIV diagnoses
fell from 69 per month in October 2015 to 15 per month in June 2017. We believe that our support for individuals taking
generic PrEP has contributed to this fall. There was a 10% increase in STI diagnoses during PrEP compared to baseline.
Strategies to reduce STIs remain crucial.
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Introduction
The incidence of HIV infections remained stable in the UK from
2005 to 2015, despite large increases in antiretroviral treatment
[1]. Pre-exposure prophylaxis (PrEP) with tenofovir disoproxil
fumarate (TDF)/emtricitabine (FTC) has been shown to
significantly reduce the risk of HIV acquisition in several large-scale
clinical trials [2–4].
The World Health Organization (WHO) updated its guidelines on
the use of antiretrovirals for HIV treatment and prevention to
recommend HIV PrEP as an additional prevention strategy [5].
As a result, several countries have included PrEP in their national
guidelines. The US, as the first country to introduce PrEP in July
2015, currently has an estimated 100,00 people taking PrEP [6].
Australia recruited 6500 patients over three clinical trials, with the
number of people on PrEP increasing rapidly [7–9]. More recently,
Belgium made the decision to provide PrEP to high-risk
populations via a reimbursement scheme [10] and Scotland has
become the first country in the UK to routinely offer PrEP to
eligible patients, which they estimate to be 1900 people [11].
However, the high cost of the branded TDF/FTC (Truvada) has
prevented many health services from funding PrEP. The National
Health Service (NHS) in England has refused to provide PrEP, but
plans to start a trial to provide PrEP to at least 10,000 people in
England in late 2017. However, to keep within the £10 million
allocated budget, TDF/FTC will need to cost substantially less than
the current NHS list price for Truvada of £4260/year [12–14].
At-risk individuals in the UK have resorted to purchasing generic
versions of PrEP on the internet, using websites such as
www.iwantprepnow.co.uk [15]. This is possible because voluntary
licensing rules have enabled manufacturing companies to produce
preparations of TDF/FTC that are bioequivalent to the branded
product. The iwantprepnow website gives guidance to patients
on purchasing generic PrEP safely through online pharmacies. It
informs patients that under UK import laws, it is legal to import
3 months of PrEP for personal use [16]. This website only lists
generic PrEP from Cipla, Mylan or the Government Pharmaceutical
Organization in Thailand, which have been officially approved by
the United States Food and Drug Administration (US FDA). For
each patient attending the clinic for therapeutic drug monitoring
(TDM), the name of the medication, manufacturer, batch number
and expiry date are recorded, a blood sample is taken and levels
of tenofovir and emtricitabine (FTC) are measured. Online
pharmacies are only listed on www.iwantprepnow.co.uk after the
sales process has been verified as safe and reliable by users or
iwantprepnow staff and once adequate drug levels have been
found. Currently, the five pharmacies recommended by
iwantprepnow are Dynamix International, Pulse Clinic, United
Pharmacies UK, All Day Chemist, and In House Pharmacy. The
current price for a 1-month supply of PrEP on this site is £39–£78
[15] compared to the commercial price of over £400/month for
non-discounted branded Truvada from Gilead Sciences [12].
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In February 2016, a service was established at 56 Dean Street (DS)
to offer plasma tenofovir and FTC TDM for people buying generic
PrEP online, alongside regular tests for sexually transmitted
infections (STIs) and renal function monitoring. A previous
publication [17] concentrated on pharmacokinetics, and addressed
initial concerns over the authenticity of the medicines purchased.
Drug concentrations of generics purchased online were consistent
with data from previously published Phase I pharmacokinetic
clinical trials. Furthermore, no fake preparations were identified
[17].
This article reports other clinical outcomes recorded in the drug
monitoring service including: number of new HIV infections,
diagnosis of other STIs, renal adverse events and use of recreational
drugs.
Methods
All HIV-negative individuals attending DS (from February 2016
to March 2017) and who reported purchasing PrEP on the internet
were offered TDM in addition to tests for HIV, hepatitis B (HBV),
hepatitis C (HCV), renal function and other STIs at first visit. Those
continuing on generic PrEP were offered regular follow-up visits
every 3 months and were encouraged to return via text message
reminders. Patients were also given risk-reduction advice.
Patient characteristics, use of recreational drugs (known in the
UK as ‘chems’), treatment regimen, days on PrEP, and name of
drug and manufacturer were recorded at initial appointment. Renal
function, HIV, HBV and HCV testing were offered at baseline and
every 3–6 months. Time on PrEP and follow-up time for HIV
diagnosis were measured from the most recent HIV test. Follow-up
time for STI diagnosis was measured from the date of starting PrEP.
For each patient attending the clinic for therapeutic drug
monitoring (TDM), the name of the medication, manufacturer,
batch number and expiry date are recorded, a blood sample is
taken and levels of tenofovir and emtricitabine (FTC) are measured.
Monitoring of STIs was consistent with national guidelines: HIV,
Chlamydia trachomatis (CT), gonorrhoea (GC) and syphilis were
routinely tested for every 3 months; HCV testing was offered to
those deemed at risk; immunity to HBV was checked at baseline
and those not immune were offered vaccination. Tests for other
STIs were performed according to clinical indication [18].
Renal function was evaluated from estimated glomerular filtration
rate (eGFR), creatinine level and/or proteinuria on urinalysis for
individuals with data available at both baseline and following PrEP
initiation. Comparison of renal function prior to and following the
use of PrEP was performed using non-parametric Wilcoxon
signed-rank test for related samples. Renal function deterioration
was defined as a >10% decline in eGFR from baseline and/or an
increase in proteinuria.
The methods for pharmacokinetic analysis have been described
previously [17]. Briefly, drug concentrations in plasma samples
taken from all patients on generic TDF/FTC were measured by
ultra-performance liquid chromatography, coupled with UV
detection with a linear range of 25–10,000 ng/mL.
This analysis was approved by Chelsea and Westminster Hospital
NHS Foundation Trust. The database used to collect patient
information was registered by the HIV/Genito-urinary Medicine
Directorate and all data were recorded anonymously.
Results
From February 2016 to March 2017, data were available for 641
patients accessing the monitoring service. Of 641 patients, 87
(14%) attended an initial appointment only and 554 (86%)
attended both an initial appointment and at least one follow-up
visit. We observed 336 person-years of PrEP use; the median
follow-up time on generic PrEP was 7.2 months. Baseline
characteristics are displayed in Table 1, compared to three
large-scale studies of PrEP in men who have sex with men (MSM).
PROUD [2] was a clinical trial in the UK of 544 MSM taking PrEP
daily. IPERGAY [4], carried out in France and Canada, enrolled
400 men to take PrEP on demand. The San Francisco Kaiser
Permanente study (KP) [19] looked at PrEP use in a real-life clinical
setting, with a cohort of 657 PrEP initiators.
Of the 641 men initiating PrEP at DS, the median age was 37,
81% of the population were white, and of those who disclosed
their method of PrEP use, 75% (481) took PrEP daily compared
to 14% (90) who used event-driven PrEP. The PrEP dosing regimen
was not stated in 11%. Reported recreational drug use in the 12
months preceding PrEP was 30% (191/641) at DS, compared to
43% in both PROUD and IPERGAY. The baseline STI rate was lower
at DS than in the other trials, 16% (91/573) compared to 25%,
63% and 28% in PROUD, IPERGAY and KP, respectively. However,
baseline STIs at DS only included diagnoses in the 3 months
pre-PrEP, compared to 12 months in the other studies. The most
common STIs diagnosed, as in the other three studies, were
Chlamydia trachomatis (42%) and gonorrhoea (40%).
At baseline, of the patients disclosing how PrEP was sourced, 202
(62%) used United Pharmacies, 55 (17%) All Day Chemist, 12
(4%) All Day Pharmacy, and 3/324 (0.9%) UK Pharmacy. Tenvir-
EM, marketed by Cipla Ltd, was the most common preparation
(97%). However, during follow-up, many patients switched from
Tenvir-EM to Ricovir-EM, marketed by Mylan, from an online
pharmacy called Dynamix [20].
In 336 person-years of follow-up, there were no cases of HIV
infection (0%, 95% CI 0%–1.1%). This is comparable to the other
three studies in Figure 1. There were no new cases of HBV
infection. Of the 492 people tested for HCV, there were two new
diagnoses during follow-up.
Table 1. Baseline characteristics for studies of HIV oral PrEP in MSM
Characteristics Clinical trial Clinical practice
IPERGAY [4]
(n=199)
PROUD [2]
(n=273)
56 Dean Street
(n=641)
San Francisco Kaiser
Permanente [19] (n=972)
MSM (percentage) 100% 100% 100% 98%
Median age (years) (IQR) 34.9 (29–43) 35 (30–43) 37 (32–45) 37 (18–68)
White race (%) 94% 81% 81% 65%
Once-daily PrEP (%) 0% 100% 75% 100%
Chem use (%) 43% 43% 30% –
Baseline STIs (%) 25% 63% 16% 28%
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STI results at baseline and follow-up are compared in Table 2. In
199 person-years of STI follow-up, 26% (142/552) of patients
were diagnosed with an STI at one or more follow-up visits,
compared to 16% (91/573) at baseline.
The incidence of STIs decreased during PrEP in the PROUD and
IPERGAY trials by 5% and 6%, respectively, whereas the 9%
increase seen at DS was lower than the Kaiser Permanente study,
which saw an increase of 22% [2,4,19].
Renal function testing at both baseline and follow-up was
conducted in 282 individuals. Baseline eGFR (>60 mL/min/
1.73 m2) and/or urinalysis was normal in 99% (537/545) of
individuals. Two (0.7%) patients had reductions in eGFR while on
PrEP; one was taking protein and creatine supplements, which
are known to underestimate true renal function, and had no
proteinuria. PrEP was not discontinued in this patient. The second
patient did not respond to efforts to contact him. Three (1%)
patients had trace proteinuria at baseline but otherwise normal
renal function results while on PrEP; two patients (0.7%) had
normal urinalysis results at baseline but showed trace proteinuria
during follow-up on PrEP.
Table 3 displays the results for recreational drug use at DS. Of
patients reporting this, 39% (191/494) reported using recreational
drugs in the 12 months before starting PrEP, and 29% (127/443)
whilst taking PrEP. The most popular drugs used were
gammahydroxybutyrate (GHB) or gammabutyrolactone (GBL)
(23%), mephedrone (21%) and methamphetamine (16%).
Injecting drug use (IDU) was reported in 61 (12%) individuals at
baseline and 42 (13%) during follow-up. Nineteen individuals
(15%) were referred for recreational drug support.
As shown in Figure 2, DS has seen a reduction in new HIV-positive
diagnoses between October 2015 (69 HIV-positive diagnoses),
and June 2017 (15 HIV-positive diagnoses). Over this time, the
number of HIV tests carried out remained constant.
Discussion
At DS, 641 MSM purchased generic TDF/FTC online over 13
months, to be used as PrEP for HIV. In 336 person-years of
follow-up, there were no new cases of HIV and no serious adverse
events. The recreational drug use reported by those taking generic
PrEP decreased during PrEP use. However, there was a 10%
increase in individuals diagnosed with an STI during PrEP follow-
up, compared to those diagnosed in the 3 months before starting
PrEP.
These results are consistent with clinical trial results with patented
TDF/FTC by Gilead; very few HIV diagnoses were seen in PROUD
and IPERGAY studies in 243 and 431 person-years of follow-up,
respectively, and including after the trials ended [21,22].
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Figure 1. Incidence rate of HIV infections per 100 person-years, 56 Dean Street compared to other studies
Table 2. Individuals diagnosed with an STI at baseline (3 months
pre-PrEP) and during follow-up
Sexually transmitted infectio Baseline Follow-up
Individuals diagnosed (n, %)
Any 91/573 (16%) 142/552 (25%)
Episodes diagnosed (n, %)
Chlamydia trachomatis (CT) 45/107 (42%) 166/373 (45%)
Gonorrhoea (GT) 43/107 (40%) 158/373 (42%)
Syphilis 12/107 (11%) 31/373 (8%)
Shigella 2/107 (2%) 0 (0%)
Herpes simplex virus (HSV) 4/107 (4%) 7/373 (2%)
Lymphogranuloma venereum
(LGV)
1/107 (1%) 11/373 (3%)
Table 3. Recreational drug use at baseline (1 year pre-PrEP) and
during follow-up
Recreational drugs used Baseline Follow-up
Individuals who used (n, %)
Any 191/494 (39%) 127/443 (29%)
Drugs used (episodes, n, %)
Cocaine 48/530 (9%) 27/315 (9%)
Methamphetamine 75/530 (14%) 51/315 (16%)
MDMA/ecstasy 48/530 (9%) 27/315 (9%)
Gammahydroxybutyrate (GHB)
or gammahydroxybutyrolactone
(GBL)
107/530 (20%) 71/315 (23%)
Methadone 38/530 (7%) 19/315 (6%)
Mephedrone 102/530 (19%) 67/315 (21%)
Amyl nitrite (poppers) 40/530 (8%) 19/315 (6%)
Amphetamine sulphate 35/530 (7%) 16/315 (5%)
Sildenafil (Viagra) 37/530 (7%) 18/315 (6%)
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Furthermore, the KP study also saw an increase in STIs during
PrEP use, supporting the evidence that STI risk reduction remains
crucial.
Although the data reported in this paper are from the original
cohort of online PrEP users attending our service, DS now monitors
over 1000 individuals on generic PrEP. In parallel with the
introduction of the PrEP monitoring service, DS has seen a
decrease in the number of HIV diagnoses overall, from 69 positive
diagnoses in October 2015, to 15 in June 2017. PrEP is believed
to have contributed to this reduction; however, there are a number
of other interventions over this time period that have influenced
HIV rates in our service. These include: the rapid STI results and
treatment within hours provided at Dean Street Express, early
treatment initiation in individuals diagnosed with HIV and provision
of HIV post-exposure prophylaxis (PEP) [23].
DS is not the only clinic to have observed a reduction in HIV
diagnoses since PrEP use became increasingly popular. Public
Health England (PHE) report a decrease in HIV diagnoses in four
other London clinics in the last quarter of 2016. However, this
is not the case for all UK clinics; PHE have found a large diversity
in HIV diagnoses UK-wide [24].
It is worth noting that the median age of PrEP users in our service
was 37 years, while the median age at diagnosis of MSM in
England in 2015 was 33, reflecting the increasing proportion of
new diagnoses in under-35-year-olds in recent years [25]. Despite
the fact that generic PrEP is significantly cheaper than Truvada,
it is likely that younger individuals would be less able to afford
it than older MSM.
Limitations
There were several limitations to this analysis. As this was a service
evaluation rather than a research study, we could not develop
rigorous baseline data, nor impose a requirement for mandatory
follow-up. This made it difficult to observe an accurate link
between baseline and follow-up with regard to STI acquisition,
recreational drug use or changes in renal function. The increase
in attendances at follow-up, as a result of measures put in place
to encourage patients to attend, may have contributed to the
increase in STIs seen in this analysis. Even so, the analysis was
still limited by lack of follow-up data for many patients. Some
patients may have attended other clinics, having only attended
DS for PrEP consultation and TDM. Others may have only attended
with symptoms, resulting in under-documenting the presence of
asymptomatic disease. Further investigation into this relationship
is needed; however, it is crucial that individuals on PrEP are
appropriately followed up to ensure that they remain adherent
to treatment and that incident STIs, including HIV infection, are
not missed and to identify and address cases of renal dysfunction.
Previously, recreational drug use at DS had not been reported
systematically. However, recently DS have found an improvement
in patient reporting as a result of a ‘no blame, no judgement’
approach. In this service, the percentage referred for recreational
drug use support was low (15%); however, walk-in support clinics
are available and widely advertised within the service.
Renal function monitoring was performed inconsistently despite
the availability of a clinic guideline, with individuals being
monitored with urinalysis or eGFR/creatinine or a combination of
both at different time points during follow-up. However, the
PROUD, IPERGAY and other PrEP studies suggest a goodTDF/FTC
safety profile with few serious attributable adverse events [2,4,26].
Screening for HCV is currently performed according to risk, so we
were unable to observe a link between HCV and PrEP. The sexual
health services at the Royal Free Hospital and the Mortimer Market
Centre in London have seen a general increase in new diagnoses
of HCV [27]. Further work is needed to ascertain whether the same
increase in new HCV diagnoses is occurring at DS; however,
anecdotal data currently suggest that this is not the case.
Generic TDF/FTC has been registered for the treatment of HIV
in 154 countries [28]; as such, the high clinical efficacy of PrEP
seen in our cohort was expected. Furthermore, generic TDF/FTC
has been added to the list of WHO prequalified medicines for the
treatment of HIV [29], not just for its prevention. Although
counterfeit medications remain a concern [30], no fake
preparations were found in any of the sources of PrEP at DS.
Although these results suggest that the pharmacies listed on the
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Figure 2. HIV tests and positive diagnoses at 56 Dean Street, London, 2015–2017
Generic PrEP analysis of outcomes 221
Journal of Virus Eradication 2017; 3: 218–222 ORIGINAL RESEARCH
www.iwantprepnow.co.uk website are safe, this may not apply for
other suppliers.
To fully ensure the safe procurement, monitoring and regulation
of generic PrEP along with the other HIV prevention tools, PrEP
should be available through the NHS. In Australia, patients can
access PrEP free of charge, but can only obtain continued supplies
if they have the appropriate follow-up tests, ensuring adequate
monitoring of adverse events and STIs.
There is thought to be a large demand for PrEP in the UK; DS
alone had interest from over 300 patients in one day following
the announcement of a commercial PrEP trial in 2016. Australia,
a country with one-fifth of the population of the UK, has recruited
over 6500 patients to PrEP trials across the country [7–9].
There were approximately 3000 new HIV infections in MSM in
the UK in 2015 [31]. The incidence of HIV infection in MSM was
estimated to be 1.3% in 2012 [23]. Using this estimate, 77 men
would need to access PrEP for 1 year to avert one HIV infection,
assuming the effectiveness seen in the PROUD and IPERGAY
studies. Therefore, if PrEP was the only contributor to HIV
prevention, 230,769 people would need to be taking PrEP for 1
year to prevent all HIV infections in MSM in the UK. To provide
this many people with access to PrEP in the UK, a considerable
reduction in the cost of antiretroviral drugs is necessary [32]. While
the NHS finalises the funding for this, personally imported generic
medication that can be purchased for only £40 a month is an
affordable option to many patients.
Given the success of PrEP in MSM, other programmes to provide
PrEP to black and minority ethnic (BME) groups, commercial sex
workers or other people at high risk of HIV infection should be
considered. However, work still needs to be done to identify
appropriate implementation models for these groups.
Summary
The price of branded PrEP from Gilead is prohibitively high for
most at-risk individuals. Online generic PrEP provides an
opportunity for patients to access HIV prevention more affordably.
A safe network of online suppliers and appropriate monitoring will
enable individuals at risk of HIV infection to access an effective
means of prevention as an interim solution until PrEP is available
on the NHS to all who need it. Similar methods of access to
generics could be established in other countries where branded
PrEP is not available.
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